S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Iraqi currency crash halts after meeting with U.S. official
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Iraqi currency crash halts after meeting with U.S. official
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Iraqi currency crash halts after meeting with U.S. official
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Iraqi currency crash halts after meeting with U.S. official
Gas prices dip in NJ, around nation as cold weather returns
NASDAQ:RGNX

REGENXBIO - RGNX Stock Forecast, Price & News

$23.75
-0.31 (-1.29%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$23.34
$24.28
50-Day Range
$21.76
$24.55
52-Week Range
$18.69
$35.73
Volume
327,093 shs
Average Volume
326,276 shs
Market Capitalization
$1.03 billion
P/E Ratio
15.32
Dividend Yield
N/A
Price Target
$41.43

REGENXBIO MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
74.4% Upside
$41.43 Price Target
Short Interest
Bearish
7.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.75mentions of REGENXBIO in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.32) to ($3.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

197th out of 1,028 stocks

Biological Products, Except Diagnostic Industry

37th out of 168 stocks

RGNX stock logo

About REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Stock News Headlines

SVB Leerink Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $14.00
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
See More Headlines
Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Company Calendar

Last Earnings
11/02/2021
Today
2/05/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RGNX
Fax
N/A
Employees
372
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.43
High Stock Price Forecast
$61.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+74.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$127.84 million
Pretax Margin
18.12%

Debt

Sales & Book Value

Annual Sales
$470.35 million
Cash Flow
$3.35 per share
Book Value
$17.87 per share

Miscellaneous

Free Float
37,796,000
Market Cap
$1.03 billion
Optionable
Optionable
Beta
1.05

Key Executives

  • Kenneth T. MillsKenneth T. Mills
    President, Chief Executive Officer & Director
  • Curran M. Simpson
    Chief Operating Officer
  • Vit Vasista
    Chief Financial Officer & Senior Vice President
  • Olivier Danos
    Chief Scientific Officer & Senior Vice President
  • Stephen PakolaStephen Pakola
    Chief Medical Officer & Senior Vice President













RGNX Stock - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGNX shares.
View RGNX analyst ratings
or view top-rated stocks.

What is REGENXBIO's stock price forecast for 2023?

6 Wall Street research analysts have issued twelve-month price objectives for REGENXBIO's stock. Their RGNX share price forecasts range from $14.00 to $61.00. On average, they anticipate the company's stock price to reach $41.43 in the next year. This suggests a possible upside of 74.4% from the stock's current price.
View analysts price targets for RGNX
or view top-rated stocks among Wall Street analysts.

How have RGNX shares performed in 2023?

REGENXBIO's stock was trading at $22.68 at the beginning of the year. Since then, RGNX stock has increased by 4.7% and is now trading at $23.75.
View the best growth stocks for 2023 here
.

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RGNX earnings forecast
.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) issued its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($1.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.50. The biotechnology company had revenue of $30.77 million for the quarter, compared to analysts' expectations of $49.35 million. REGENXBIO had a net margin of 15.34% and a trailing twelve-month return on equity of 12.22%. During the same period in the previous year, the company earned $0.23 EPS.

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.24%), Monarch Partners Asset Management LLC (0.17%), Harbor Capital Advisors Inc. (0.06%), SummerHaven Investment Management LLC (0.06%), Essex Investment Management Co. LLC (0.06%) and Yousif Capital Management LLC (0.06%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends
.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $23.75.

How much money does REGENXBIO make?

REGENXBIO (NASDAQ:RGNX) has a market capitalization of $1.03 billion and generates $480.03 million in revenue each year. The biotechnology company earns $127.84 million in net income (profit) each year or $1.55 on an earnings per share basis.

How many employees does REGENXBIO have?

The company employs 372 workers across the globe.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com.

This page (NASDAQ:RGNX) was last updated on 2/5/2023 by MarketBeat.com Staff